| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tuberculosis | 18 | 2022 | 555 | 3.340 |
Why?
|
| Kidney Transplantation | 24 | 2026 | 563 | 2.470 |
Why?
|
| Magnetic Resonance Imaging, Cine | 14 | 2025 | 172 | 1.950 |
Why?
|
| Aortic Valve Insufficiency | 10 | 2025 | 149 | 1.790 |
Why?
|
| Mycobacterium tuberculosis | 12 | 2022 | 427 | 1.710 |
Why?
|
| Interferon-gamma Release Tests | 6 | 2019 | 89 | 1.540 |
Why?
|
| Coinfection | 4 | 2019 | 188 | 1.220 |
Why?
|
| Liver Transplantation | 12 | 2026 | 1138 | 1.140 |
Why?
|
| Laparoscopy | 8 | 2024 | 541 | 1.140 |
Why?
|
| Graft Rejection | 13 | 2026 | 558 | 1.040 |
Why?
|
| Hernia, Hiatal | 7 | 2025 | 58 | 1.030 |
Why?
|
| Middle Aged | 84 | 2026 | 28517 | 1.030 |
Why?
|
| Graft Survival | 13 | 2026 | 462 | 1.030 |
Why?
|
| Mitral Valve Insufficiency | 6 | 2025 | 180 | 1.020 |
Why?
|
| Retrospective Studies | 72 | 2026 | 17673 | 1.010 |
Why?
|
| Tuberculosis, Pulmonary | 5 | 2021 | 239 | 0.970 |
Why?
|
| HIV Infections | 9 | 2025 | 2036 | 0.960 |
Why?
|
| Prognosis | 31 | 2026 | 4913 | 0.940 |
Why?
|
| Predictive Value of Tests | 18 | 2025 | 2303 | 0.940 |
Why?
|
| Male | 105 | 2026 | 64772 | 0.870 |
Why?
|
| Humans | 155 | 2026 | 130870 | 0.830 |
Why?
|
| Female | 105 | 2026 | 70560 | 0.830 |
Why?
|
| Living Donors | 8 | 2024 | 112 | 0.830 |
Why?
|
| Aged | 56 | 2026 | 20974 | 0.810 |
Why?
|
| Postoperative Complications | 16 | 2026 | 3131 | 0.790 |
Why?
|
| Heller Myotomy | 2 | 2021 | 9 | 0.780 |
Why?
|
| Antitubercular Agents | 5 | 2019 | 269 | 0.770 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 894 | 0.760 |
Why?
|
| Esophageal Achalasia | 2 | 2021 | 46 | 0.750 |
Why?
|
| Heart Transplantation | 7 | 2024 | 833 | 0.740 |
Why?
|
| Adult | 65 | 2026 | 31245 | 0.740 |
Why?
|
| Fundoplication | 8 | 2025 | 70 | 0.720 |
Why?
|
| Ventricular Function, Left | 9 | 2026 | 549 | 0.700 |
Why?
|
| Robotic Surgical Procedures | 3 | 2024 | 224 | 0.700 |
Why?
|
| Texas | 17 | 2026 | 3635 | 0.700 |
Why?
|
| Mass Screening | 3 | 2019 | 808 | 0.690 |
Why?
|
| Risk Factors | 35 | 2026 | 10978 | 0.680 |
Why?
|
| Ventricular Remodeling | 7 | 2025 | 154 | 0.670 |
Why?
|
| Cardiomyopathies | 5 | 2026 | 518 | 0.660 |
Why?
|
| Pancreas Transplantation | 4 | 2024 | 30 | 0.640 |
Why?
|
| Heart-Assist Devices | 7 | 2024 | 1014 | 0.640 |
Why?
|
| Polyomavirus Infections | 5 | 2024 | 87 | 0.640 |
Why?
|
| Pyloromyotomy | 1 | 2019 | 3 | 0.620 |
Why?
|
| Prevalence | 10 | 2025 | 2694 | 0.600 |
Why?
|
| Kidney Failure, Chronic | 7 | 2026 | 941 | 0.600 |
Why?
|
| Analgesics, Opioid | 4 | 2026 | 484 | 0.590 |
Why?
|
| Lung Transplantation | 6 | 2024 | 355 | 0.580 |
Why?
|
| Aortic Valve | 4 | 2025 | 456 | 0.580 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2019 | 31 | 0.570 |
Why?
|
| Biological Assay | 1 | 2019 | 106 | 0.560 |
Why?
|
| General Surgery | 4 | 2021 | 225 | 0.560 |
Why?
|
| Radiography, Thoracic | 2 | 2016 | 144 | 0.530 |
Why?
|
| Heart Failure | 10 | 2025 | 2335 | 0.510 |
Why?
|
| BK Virus | 4 | 2024 | 58 | 0.500 |
Why?
|
| Transplant Recipients | 8 | 2022 | 228 | 0.500 |
Why?
|
| Risk Assessment | 11 | 2026 | 3694 | 0.500 |
Why?
|
| Residence Characteristics | 3 | 2025 | 292 | 0.500 |
Why?
|
| Viremia | 4 | 2025 | 131 | 0.490 |
Why?
|
| Cholangiocarcinoma | 3 | 2026 | 126 | 0.490 |
Why?
|
| Bile Duct Neoplasms | 3 | 2026 | 135 | 0.490 |
Why?
|
| Tumor Virus Infections | 4 | 2024 | 131 | 0.480 |
Why?
|
| Heart Neoplasms | 3 | 2022 | 108 | 0.470 |
Why?
|
| Patient Readmission | 5 | 2025 | 431 | 0.470 |
Why?
|
| Treatment Outcome | 28 | 2026 | 12914 | 0.470 |
Why?
|
| Lung Neoplasms | 5 | 2025 | 1548 | 0.460 |
Why?
|
| ROC Curve | 5 | 2024 | 607 | 0.460 |
Why?
|
| Isoantibodies | 4 | 2026 | 62 | 0.460 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2025 | 79 | 0.420 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 342 | 0.410 |
Why?
|
| Adolescent | 25 | 2026 | 20820 | 0.410 |
Why?
|
| Glomerular Filtration Rate | 9 | 2026 | 569 | 0.410 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 233 | 0.410 |
Why?
|
| Follow-Up Studies | 19 | 2026 | 5199 | 0.410 |
Why?
|
| Prospective Studies | 19 | 2026 | 6450 | 0.390 |
Why?
|
| Tissue Donors | 5 | 2024 | 504 | 0.370 |
Why?
|
| Young Adult | 18 | 2026 | 10042 | 0.370 |
Why?
|
| Proportional Hazards Models | 10 | 2021 | 1405 | 0.370 |
Why?
|
| Urban Health Services | 1 | 2011 | 15 | 0.360 |
Why?
|
| Obesity | 5 | 2022 | 2387 | 0.360 |
Why?
|
| Hypertension | 5 | 2025 | 1354 | 0.350 |
Why?
|
| Vietnam | 3 | 2019 | 65 | 0.350 |
Why?
|
| Deglutition Disorders | 2 | 2025 | 136 | 0.350 |
Why?
|
| Time Factors | 13 | 2026 | 6217 | 0.340 |
Why?
|
| Tissue and Organ Procurement | 4 | 2024 | 255 | 0.340 |
Why?
|
| Internship and Residency | 5 | 2021 | 1216 | 0.340 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 137 | 0.330 |
Why?
|
| HLA Antigens | 4 | 2026 | 226 | 0.330 |
Why?
|
| Renal Insufficiency | 3 | 2022 | 256 | 0.330 |
Why?
|
| Immunosuppressive Agents | 6 | 2020 | 665 | 0.330 |
Why?
|
| Child | 23 | 2026 | 26218 | 0.320 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2026 | 1006 | 0.320 |
Why?
|
| Organ Transplantation | 2 | 2022 | 170 | 0.310 |
Why?
|
| Gastroesophageal Reflux | 2 | 2025 | 333 | 0.310 |
Why?
|
| Learning | 3 | 2022 | 370 | 0.300 |
Why?
|
| Child, Preschool | 13 | 2026 | 15018 | 0.300 |
Why?
|
| Kidney | 7 | 2024 | 1283 | 0.290 |
Why?
|
| Sarcoma | 2 | 2022 | 219 | 0.290 |
Why?
|
| Stroke Volume | 7 | 2026 | 541 | 0.290 |
Why?
|
| Liver Neoplasms | 3 | 2026 | 1396 | 0.290 |
Why?
|
| Pneumonectomy | 3 | 2025 | 147 | 0.280 |
Why?
|
| Reproducibility of Results | 9 | 2024 | 2925 | 0.280 |
Why?
|
| Nephrectomy | 4 | 2021 | 156 | 0.280 |
Why?
|
| Antilymphocyte Serum | 2 | 2020 | 44 | 0.280 |
Why?
|
| Viral Load | 3 | 2025 | 406 | 0.280 |
Why?
|
| Fibrosis | 7 | 2024 | 421 | 0.270 |
Why?
|
| Adenoidectomy | 2 | 2025 | 84 | 0.270 |
Why?
|
| Ventricular Function, Right | 2 | 2026 | 127 | 0.270 |
Why?
|
| Comorbidity | 4 | 2021 | 1587 | 0.260 |
Why?
|
| Health Personnel | 5 | 2019 | 550 | 0.260 |
Why?
|
| Area Under Curve | 4 | 2024 | 319 | 0.260 |
Why?
|
| Heart Diseases | 2 | 2023 | 504 | 0.260 |
Why?
|
| Antipsychotic Agents | 3 | 2015 | 364 | 0.260 |
Why?
|
| Databases, Factual | 4 | 2019 | 1228 | 0.250 |
Why?
|
| Myocardium | 3 | 2021 | 863 | 0.250 |
Why?
|
| Cohort Studies | 10 | 2026 | 5095 | 0.250 |
Why?
|
| Tonsillectomy | 2 | 2025 | 112 | 0.250 |
Why?
|
| Enzyme-Linked Immunospot Assay | 2 | 2016 | 9 | 0.250 |
Why?
|
| Population Surveillance | 2 | 2019 | 396 | 0.250 |
Why?
|
| Infant, Newborn | 7 | 2025 | 8509 | 0.250 |
Why?
|
| Infant | 9 | 2026 | 13299 | 0.240 |
Why?
|
| Kidney Function Tests | 3 | 2026 | 136 | 0.240 |
Why?
|
| Time-to-Treatment | 2 | 2026 | 210 | 0.240 |
Why?
|
| Thrombosis | 2 | 2022 | 498 | 0.240 |
Why?
|
| Preoperative Care | 2 | 2025 | 359 | 0.240 |
Why?
|
| Schools | 2 | 2025 | 234 | 0.240 |
Why?
|
| Bundle of His | 1 | 2026 | 16 | 0.240 |
Why?
|
| Cross-Sectional Studies | 8 | 2025 | 3807 | 0.230 |
Why?
|
| Age Factors | 4 | 2022 | 2842 | 0.230 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 361 | 0.230 |
Why?
|
| Donor Selection | 3 | 2024 | 58 | 0.230 |
Why?
|
| Latent Tuberculosis | 2 | 2016 | 76 | 0.230 |
Why?
|
| Atrial Remodeling | 1 | 2025 | 16 | 0.230 |
Why?
|
| Herniorrhaphy | 3 | 2021 | 72 | 0.230 |
Why?
|
| Hydrocodone | 1 | 2025 | 36 | 0.230 |
Why?
|
| Anorexia Nervosa | 1 | 2025 | 31 | 0.230 |
Why?
|
| Telomere Homeostasis | 1 | 2025 | 48 | 0.230 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2024 | 228 | 0.230 |
Why?
|
| Intraoperative Care | 1 | 2026 | 122 | 0.220 |
Why?
|
| Observer Variation | 2 | 2024 | 318 | 0.220 |
Why?
|
| Fentanyl | 1 | 2025 | 55 | 0.220 |
Why?
|
| Length of Stay | 5 | 2026 | 1396 | 0.220 |
Why?
|
| Emergency Service, Hospital | 2 | 2025 | 1210 | 0.220 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2026 | 48 | 0.220 |
Why?
|
| Antigens, Bacterial | 2 | 2017 | 315 | 0.220 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 6801 | 0.220 |
Why?
|
| Psychotherapy, Group | 1 | 2025 | 58 | 0.220 |
Why?
|
| Anemia, Aplastic | 1 | 2025 | 61 | 0.220 |
Why?
|
| Survival Rate | 7 | 2026 | 2140 | 0.220 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 2024 | 16 | 0.220 |
Why?
|
| Mastoidectomy | 1 | 2024 | 5 | 0.220 |
Why?
|
| Weaning | 2 | 2021 | 51 | 0.220 |
Why?
|
| Troponin | 1 | 2025 | 69 | 0.220 |
Why?
|
| Registries | 4 | 2025 | 1617 | 0.220 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2026 | 133 | 0.220 |
Why?
|
| Cholesteatoma, Middle Ear | 1 | 2024 | 14 | 0.210 |
Why?
|
| Lung Diseases | 2 | 2019 | 396 | 0.210 |
Why?
|
| Risperidone | 2 | 2015 | 60 | 0.210 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2025 | 78 | 0.210 |
Why?
|
| Acetaminophen | 1 | 2025 | 99 | 0.210 |
Why?
|
| Spinal Fusion | 1 | 2026 | 133 | 0.210 |
Why?
|
| Anesthesia, General | 1 | 2025 | 143 | 0.210 |
Why?
|
| Status Epilepticus | 1 | 2026 | 157 | 0.210 |
Why?
|
| Metabolic Syndrome | 2 | 2020 | 366 | 0.210 |
Why?
|
| Research Design | 2 | 2019 | 719 | 0.210 |
Why?
|
| Logistic Models | 4 | 2018 | 1805 | 0.210 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2024 | 79 | 0.210 |
Why?
|
| Scoliosis | 1 | 2026 | 157 | 0.210 |
Why?
|
| Telomere | 1 | 2025 | 219 | 0.210 |
Why?
|
| United States | 13 | 2025 | 11865 | 0.200 |
Why?
|
| Exercise Test | 1 | 2025 | 235 | 0.200 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2025 | 753 | 0.200 |
Why?
|
| Immunoglobulin G | 3 | 2022 | 790 | 0.200 |
Why?
|
| Hypoxia | 1 | 2025 | 247 | 0.200 |
Why?
|
| Plasma Cells | 1 | 2024 | 54 | 0.200 |
Why?
|
| Mitral Valve | 1 | 2025 | 246 | 0.200 |
Why?
|
| Anti-Retroviral Agents | 1 | 2025 | 154 | 0.200 |
Why?
|
| Biphenyl Compounds | 1 | 2024 | 75 | 0.200 |
Why?
|
| Kidney Diseases | 2 | 2024 | 472 | 0.200 |
Why?
|
| Biomarkers | 7 | 2026 | 3400 | 0.200 |
Why?
|
| Chronic Pain | 1 | 2026 | 162 | 0.200 |
Why?
|
| Anticonvulsants | 1 | 2026 | 360 | 0.200 |
Why?
|
| Esophageal Fistula | 1 | 2023 | 15 | 0.200 |
Why?
|
| Cicatrix | 2 | 2023 | 125 | 0.200 |
Why?
|
| Tricuspid Valve Insufficiency | 2 | 2020 | 61 | 0.190 |
Why?
|
| Tacrolimus | 2 | 2020 | 102 | 0.190 |
Why?
|
| Migraine Disorders | 1 | 2024 | 61 | 0.190 |
Why?
|
| Heart Rate | 1 | 2026 | 576 | 0.190 |
Why?
|
| Faculty | 1 | 2023 | 96 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 3 | 2021 | 394 | 0.190 |
Why?
|
| Obesity, Morbid | 2 | 2022 | 230 | 0.180 |
Why?
|
| Tuberculosis, Lymph Node | 2 | 2019 | 22 | 0.180 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2026 | 493 | 0.180 |
Why?
|
| Brain Death | 2 | 2021 | 74 | 0.180 |
Why?
|
| Sickle Cell Trait | 1 | 2022 | 10 | 0.180 |
Why?
|
| Phlebotomy | 2 | 2019 | 20 | 0.180 |
Why?
|
| Extracellular Matrix | 2 | 2020 | 235 | 0.180 |
Why?
|
| Blood Glucose | 3 | 2022 | 1114 | 0.180 |
Why?
|
| Solanum tuberosum | 1 | 2022 | 12 | 0.180 |
Why?
|
| Carcinoid Tumor | 1 | 2022 | 24 | 0.180 |
Why?
|
| Odds Ratio | 2 | 2018 | 1215 | 0.180 |
Why?
|
| Factor Xa Inhibitors | 1 | 2022 | 59 | 0.180 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2025 | 239 | 0.180 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 41 | 0.180 |
Why?
|
| Agammaglobulinemia | 1 | 2022 | 43 | 0.180 |
Why?
|
| Fibromuscular Dysplasia | 1 | 2021 | 6 | 0.180 |
Why?
|
| Anti-HIV Agents | 1 | 2025 | 351 | 0.180 |
Why?
|
| Quality Improvement | 2 | 2026 | 699 | 0.170 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2021 | 38 | 0.170 |
Why?
|
| Bacterial Proteins | 2 | 2017 | 940 | 0.170 |
Why?
|
| Acute Coronary Syndrome | 1 | 2025 | 247 | 0.170 |
Why?
|
| Postprandial Period | 1 | 2022 | 87 | 0.170 |
Why?
|
| Hemangiosarcoma | 1 | 2022 | 47 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2021 | 1448 | 0.170 |
Why?
|
| Extracellular Vesicles | 1 | 2022 | 75 | 0.170 |
Why?
|
| Hospitals, Public | 1 | 2021 | 49 | 0.170 |
Why?
|
| Virtual Reality | 1 | 2021 | 35 | 0.170 |
Why?
|
| Hemorrhage | 2 | 2022 | 493 | 0.170 |
Why?
|
| Feasibility Studies | 4 | 2025 | 813 | 0.170 |
Why?
|
| Anticoagulants | 2 | 2022 | 605 | 0.170 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2020 | 11 | 0.170 |
Why?
|
| Seizures | 1 | 2026 | 876 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2025 | 1082 | 0.170 |
Why?
|
| Heart Ventricles | 2 | 2025 | 762 | 0.160 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 1167 | 0.160 |
Why?
|
| HIV Protease Inhibitors | 1 | 2020 | 45 | 0.160 |
Why?
|
| Education, Distance | 1 | 2021 | 69 | 0.160 |
Why?
|
| Ambulatory Care | 1 | 2024 | 400 | 0.160 |
Why?
|
| Professional Autonomy | 1 | 2020 | 29 | 0.160 |
Why?
|
| Paraganglioma | 1 | 2020 | 22 | 0.160 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2020 | 19 | 0.160 |
Why?
|
| Minisatellite Repeats | 2 | 2017 | 43 | 0.160 |
Why?
|
| Kidney Calculi | 1 | 2020 | 40 | 0.160 |
Why?
|
| Public Opinion | 1 | 2020 | 63 | 0.160 |
Why?
|
| Extracellular Fluid | 1 | 2019 | 11 | 0.160 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 9 | 0.160 |
Why?
|
| Mortality | 2 | 2020 | 258 | 0.160 |
Why?
|
| Peripheral Arterial Disease | 1 | 2024 | 321 | 0.160 |
Why?
|
| Pediatric Obesity | 1 | 2025 | 412 | 0.160 |
Why?
|
| Cytokines | 1 | 2026 | 1336 | 0.160 |
Why?
|
| Plasma | 1 | 2020 | 103 | 0.160 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2020 | 40 | 0.150 |
Why?
|
| Palliative Care | 1 | 2024 | 446 | 0.150 |
Why?
|
| Esophageal Sphincter, Lower | 1 | 2019 | 14 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2023 | 321 | 0.150 |
Why?
|
| Prediabetic State | 1 | 2020 | 69 | 0.150 |
Why?
|
| Organ Preservation | 1 | 2020 | 61 | 0.150 |
Why?
|
| Tuberculosis, Laryngeal | 1 | 2019 | 2 | 0.150 |
Why?
|
| Tuberculosis, Oral | 1 | 2019 | 3 | 0.150 |
Why?
|
| Hypertension, Pulmonary | 2 | 2024 | 451 | 0.150 |
Why?
|
| Foreign Professional Personnel | 1 | 2019 | 2 | 0.150 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 43 | 0.150 |
Why?
|
| Vascular Patency | 1 | 2020 | 180 | 0.150 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 354 | 0.150 |
Why?
|
| Specialties, Surgical | 1 | 2020 | 90 | 0.150 |
Why?
|
| Attitude to Health | 1 | 2020 | 244 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2023 | 381 | 0.150 |
Why?
|
| Sputum | 3 | 2017 | 115 | 0.150 |
Why?
|
| Teaching | 1 | 2020 | 198 | 0.150 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2020 | 86 | 0.150 |
Why?
|
| Tricuspid Valve | 1 | 2019 | 59 | 0.150 |
Why?
|
| Incidence | 6 | 2026 | 3336 | 0.140 |
Why?
|
| Angioplasty, Balloon | 1 | 2020 | 125 | 0.140 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 63 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2025 | 623 | 0.140 |
Why?
|
| Quetiapine Fumarate | 2 | 2015 | 15 | 0.140 |
Why?
|
| Methacholine Chloride | 1 | 2018 | 16 | 0.140 |
Why?
|
| Datasets as Topic | 1 | 2019 | 100 | 0.140 |
Why?
|
| Blood Specimen Collection | 1 | 2019 | 47 | 0.140 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 216 | 0.140 |
Why?
|
| Bronchial Hyperreactivity | 1 | 2018 | 34 | 0.140 |
Why?
|
| Mental Disorders | 3 | 2015 | 896 | 0.140 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 241 | 0.140 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 2119 | 0.140 |
Why?
|
| Contrast Media | 4 | 2023 | 491 | 0.140 |
Why?
|
| Endothelium, Vascular | 1 | 2021 | 471 | 0.140 |
Why?
|
| Shock, Cardiogenic | 1 | 2020 | 173 | 0.140 |
Why?
|
| Vascular Diseases | 1 | 2020 | 153 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2018 | 95 | 0.140 |
Why?
|
| Troponin T | 1 | 2019 | 255 | 0.140 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2017 | 14 | 0.140 |
Why?
|
| Waiting Lists | 1 | 2020 | 245 | 0.140 |
Why?
|
| End Stage Liver Disease | 1 | 2020 | 194 | 0.140 |
Why?
|
| Primary Graft Dysfunction | 1 | 2018 | 41 | 0.130 |
Why?
|
| Epidemiological Monitoring | 1 | 2018 | 72 | 0.130 |
Why?
|
| Gadolinium | 3 | 2023 | 110 | 0.130 |
Why?
|
| Communicable Diseases | 1 | 2020 | 159 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1290 | 0.130 |
Why?
|
| Coronary Artery Disease | 1 | 2025 | 892 | 0.130 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2024 | 752 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 499 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2019 | 230 | 0.130 |
Why?
|
| Telemedicine | 1 | 2024 | 515 | 0.130 |
Why?
|
| Interspersed Repetitive Sequences | 1 | 2017 | 25 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2017 | 235 | 0.130 |
Why?
|
| Sensitivity and Specificity | 5 | 2021 | 2115 | 0.130 |
Why?
|
| Weight Gain | 1 | 2020 | 380 | 0.130 |
Why?
|
| Pandemics | 2 | 2022 | 1158 | 0.130 |
Why?
|
| Diabetes Complications | 1 | 2019 | 197 | 0.130 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 784 | 0.130 |
Why?
|
| Immunoassay | 1 | 2017 | 125 | 0.130 |
Why?
|
| Intensive Care Units | 1 | 2021 | 522 | 0.130 |
Why?
|
| Surgical Mesh | 1 | 2017 | 64 | 0.130 |
Why?
|
| Faculty, Medical | 1 | 2020 | 279 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
|
| Sepsis | 1 | 2021 | 497 | 0.130 |
Why?
|
| Allografts | 3 | 2026 | 218 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2018 | 256 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 206 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2025 | 3827 | 0.130 |
Why?
|
| Bacteriological Techniques | 1 | 2017 | 86 | 0.130 |
Why?
|
| Bradykinin | 1 | 2016 | 42 | 0.120 |
Why?
|
| Models, Biological | 1 | 2022 | 1391 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2017 | 144 | 0.120 |
Why?
|
| Automation, Laboratory | 1 | 2016 | 17 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1279 | 0.120 |
Why?
|
| Body Mass Index | 5 | 2022 | 1681 | 0.120 |
Why?
|
| Scleroderma, Systemic | 1 | 2018 | 131 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2019 | 231 | 0.120 |
Why?
|
| Immunologic Memory | 1 | 2017 | 194 | 0.120 |
Why?
|
| Multivariate Analysis | 1 | 2019 | 1380 | 0.120 |
Why?
|
| Cytomegalovirus Infections | 1 | 2018 | 220 | 0.120 |
Why?
|
| Severity of Illness Index | 4 | 2025 | 3040 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 171 | 0.120 |
Why?
|
| Patient Selection | 1 | 2020 | 723 | 0.120 |
Why?
|
| Fever | 1 | 2018 | 306 | 0.120 |
Why?
|
| Likelihood Functions | 1 | 2016 | 117 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 734 | 0.110 |
Why?
|
| Genetic Loci | 1 | 2017 | 356 | 0.110 |
Why?
|
| HIV-1 | 1 | 2019 | 484 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 364 | 0.110 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2018 | 205 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.110 |
Why?
|
| Manuals as Topic | 1 | 2014 | 10 | 0.110 |
Why?
|
| Dibenzothiazepines | 1 | 2014 | 12 | 0.110 |
Why?
|
| Quality of Life | 1 | 2024 | 2082 | 0.110 |
Why?
|
| Interferon-gamma | 1 | 2016 | 548 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2026 | 1876 | 0.100 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 832 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 300 | 0.100 |
Why?
|
| Insulin | 2 | 2020 | 1148 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2019 | 637 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2022 | 1311 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2024 | 887 | 0.090 |
Why?
|
| Dyslipidemias | 1 | 2015 | 252 | 0.090 |
Why?
|
| Renal Dialysis | 1 | 2020 | 949 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 1157 | 0.090 |
Why?
|
| Surveys and Questionnaires | 5 | 2020 | 4017 | 0.090 |
Why?
|
| Diagnostic Errors | 1 | 2016 | 346 | 0.090 |
Why?
|
| Socioeconomic Factors | 2 | 2025 | 896 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2026 | 669 | 0.090 |
Why?
|
| Proteinuria | 2 | 2022 | 108 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2021 | 3393 | 0.090 |
Why?
|
| Algorithms | 2 | 2024 | 1682 | 0.090 |
Why?
|
| Psychiatry | 1 | 2014 | 269 | 0.080 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2022 | 146 | 0.080 |
Why?
|
| Biopsy | 2 | 2024 | 1244 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1318 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2021 | 90 | 0.080 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 851 | 0.080 |
Why?
|
| Immunization, Passive | 2 | 2020 | 122 | 0.080 |
Why?
|
| Pediatrics | 2 | 2024 | 1247 | 0.080 |
Why?
|
| Propensity Score | 2 | 2021 | 272 | 0.080 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 1493 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 1487 | 0.070 |
Why?
|
| Heart Atria | 2 | 2023 | 335 | 0.070 |
Why?
|
| Risk | 2 | 2021 | 729 | 0.070 |
Why?
|
| Transcriptome | 1 | 2016 | 1129 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2020 | 330 | 0.070 |
Why?
|
| Patient Satisfaction | 2 | 2025 | 459 | 0.070 |
Why?
|
| Chronic Disease | 2 | 2024 | 1238 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2020 | 392 | 0.070 |
Why?
|
| Reoperation | 2 | 2023 | 834 | 0.070 |
Why?
|
| Genotype | 3 | 2017 | 2606 | 0.060 |
Why?
|
| Disease-Free Survival | 2 | 2020 | 904 | 0.060 |
Why?
|
| Cholesterol | 2 | 2021 | 541 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 416 | 0.060 |
Why?
|
| Overweight | 2 | 2022 | 377 | 0.060 |
Why?
|
| Granulocytes | 1 | 2025 | 68 | 0.060 |
Why?
|
| Asymptomatic Diseases | 1 | 2025 | 77 | 0.060 |
Why?
|
| Tanzania | 1 | 2025 | 67 | 0.060 |
Why?
|
| Incidental Findings | 1 | 2026 | 124 | 0.060 |
Why?
|
| Tympanoplasty | 1 | 2024 | 11 | 0.050 |
Why?
|
| Mastoid | 1 | 2024 | 23 | 0.050 |
Why?
|
| Conservative Treatment | 1 | 2025 | 47 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2025 | 273 | 0.050 |
Why?
|
| Myocardial Revascularization | 1 | 2025 | 100 | 0.050 |
Why?
|
| Oximetry | 1 | 2025 | 176 | 0.050 |
Why?
|
| Hospitalization | 2 | 2025 | 1928 | 0.050 |
Why?
|
| Abatacept | 1 | 2024 | 22 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 351 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2024 | 53 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2025 | 348 | 0.050 |
Why?
|
| Clinical Competence | 2 | 2021 | 1055 | 0.050 |
Why?
|
| Tetrazoles | 1 | 2024 | 72 | 0.050 |
Why?
|
| Microscopy | 1 | 2024 | 118 | 0.050 |
Why?
|
| Social Class | 1 | 2025 | 206 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2025 | 771 | 0.050 |
Why?
|
| Action Potentials | 1 | 2026 | 473 | 0.050 |
Why?
|
| Hypertrophy | 1 | 2023 | 102 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2024 | 155 | 0.050 |
Why?
|
| Factor Xa | 1 | 2022 | 15 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2017 | 1457 | 0.050 |
Why?
|
| Diastole | 1 | 2023 | 180 | 0.050 |
Why?
|
| Desensitization, Immunologic | 1 | 2024 | 104 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2024 | 236 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2025 | 836 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2022 | 48 | 0.050 |
Why?
|
| Faecalibacterium | 1 | 2022 | 2 | 0.050 |
Why?
|
| Hemolysis | 1 | 2022 | 89 | 0.050 |
Why?
|
| Glycemic Index | 1 | 2022 | 20 | 0.050 |
Why?
|
| Surgical Stapling | 1 | 2022 | 18 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2023 | 318 | 0.040 |
Why?
|
| Anastomotic Leak | 1 | 2022 | 36 | 0.040 |
Why?
|
| Fibrinogen | 1 | 2022 | 167 | 0.040 |
Why?
|
| Esophagogastric Junction | 1 | 2021 | 37 | 0.040 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2022 | 108 | 0.040 |
Why?
|
| Disease Progression | 2 | 2020 | 2212 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2022 | 73 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2021 | 54 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2026 | 858 | 0.040 |
Why?
|
| Renal Artery | 1 | 2021 | 70 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2023 | 325 | 0.040 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2021 | 104 | 0.040 |
Why?
|
| Postoperative Hemorrhage | 1 | 2022 | 82 | 0.040 |
Why?
|
| Virulence Factors | 1 | 2022 | 181 | 0.040 |
Why?
|
| Gastrectomy | 1 | 2022 | 107 | 0.040 |
Why?
|
| Fibrinolytic Agents | 1 | 2022 | 193 | 0.040 |
Why?
|
| Rifampin | 1 | 2021 | 122 | 0.040 |
Why?
|
| Inpatients | 1 | 2025 | 558 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2024 | 407 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2022 | 324 | 0.040 |
Why?
|
| Appendectomy | 1 | 2021 | 88 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 57 | 0.040 |
Why?
|
| Fasting | 1 | 2022 | 306 | 0.040 |
Why?
|
| Blood Component Transfusion | 1 | 2020 | 58 | 0.040 |
Why?
|
| Vasodilation | 1 | 2021 | 175 | 0.040 |
Why?
|
| Bayes Theorem | 1 | 2021 | 308 | 0.040 |
Why?
|
| Medical Futility | 1 | 2020 | 40 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2021 | 265 | 0.040 |
Why?
|
| Death | 1 | 2021 | 78 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2022 | 702 | 0.040 |
Why?
|
| Cold Ischemia | 1 | 2020 | 28 | 0.040 |
Why?
|
| Operative Time | 1 | 2021 | 200 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 1 | 2020 | 232 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 522 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 235 | 0.040 |
Why?
|
| Extracellular Space | 1 | 2019 | 79 | 0.040 |
Why?
|
| Gadolinium DTPA | 1 | 2019 | 49 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2022 | 301 | 0.040 |
Why?
|
| Ablation Techniques | 1 | 2020 | 30 | 0.040 |
Why?
|
| Vegetables | 1 | 2022 | 267 | 0.040 |
Why?
|
| Thrombelastography | 1 | 2020 | 66 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2019 | 79 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 211 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2021 | 312 | 0.040 |
Why?
|
| Vascular Resistance | 1 | 2020 | 182 | 0.040 |
Why?
|
| Calibration | 1 | 2019 | 92 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 331 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2020 | 239 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2020 | 227 | 0.040 |
Why?
|
| Occupational Health | 1 | 2019 | 47 | 0.040 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2018 | 8 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2021 | 317 | 0.040 |
Why?
|
| Heart | 1 | 2023 | 662 | 0.040 |
Why?
|
| Triglycerides | 1 | 2021 | 606 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 689 | 0.040 |
Why?
|
| Opportunistic Infections | 1 | 2019 | 71 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2020 | 166 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 86 | 0.040 |
Why?
|
| Anxiety | 1 | 2025 | 1004 | 0.040 |
Why?
|
| Blood Flow Velocity | 1 | 2020 | 419 | 0.030 |
Why?
|
| Fluoroquinolones | 1 | 2019 | 93 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 112 | 0.030 |
Why?
|
| Organ Size | 1 | 2019 | 421 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 438 | 0.030 |
Why?
|
| Mycophenolic Acid | 1 | 2018 | 62 | 0.030 |
Why?
|
| Reference Values | 1 | 2019 | 680 | 0.030 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2019 | 194 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2019 | 760 | 0.030 |
Why?
|
| Spatio-Temporal Analysis | 1 | 2017 | 16 | 0.030 |
Why?
|
| Hyperlipidemias | 1 | 2019 | 189 | 0.030 |
Why?
|
| Geographic Information Systems | 1 | 2017 | 37 | 0.030 |
Why?
|
| Glucose | 1 | 2022 | 855 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2021 | 1501 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 632 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2019 | 502 | 0.030 |
Why?
|
| Stomach | 1 | 2019 | 272 | 0.030 |
Why?
|
| Students, Medical | 1 | 2021 | 343 | 0.030 |
Why?
|
| Maryland | 1 | 2016 | 39 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2017 | 145 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2018 | 258 | 0.030 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 165 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 522 | 0.030 |
Why?
|
| Georgia | 1 | 2016 | 46 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 818 | 0.030 |
Why?
|
| Global Health | 1 | 2021 | 628 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2016 | 65 | 0.030 |
Why?
|
| Massachusetts | 1 | 2016 | 115 | 0.030 |
Why?
|
| Nanomedicine | 1 | 2016 | 27 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 237 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2019 | 344 | 0.030 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2020 | 428 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 143 | 0.030 |
Why?
|
| Smoking | 1 | 2021 | 923 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 1004 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2017 | 362 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2022 | 2566 | 0.030 |
Why?
|
| British Columbia | 1 | 2015 | 10 | 0.030 |
Why?
|
| Tuberculin Test | 1 | 2016 | 120 | 0.030 |
Why?
|
| Remission Induction | 1 | 2016 | 302 | 0.030 |
Why?
|
| Radiography | 1 | 2018 | 754 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2018 | 433 | 0.030 |
Why?
|
| Waist Circumference | 1 | 2015 | 93 | 0.030 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2015 | 45 | 0.030 |
Why?
|
| Disease Outbreaks | 1 | 2017 | 316 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1639 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 320 | 0.030 |
Why?
|
| Diet | 1 | 2022 | 1100 | 0.030 |
Why?
|
| Curriculum | 1 | 2020 | 785 | 0.030 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2015 | 82 | 0.030 |
Why?
|
| Autoimmunity | 1 | 2016 | 176 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2017 | 464 | 0.030 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 385 | 0.030 |
Why?
|
| Mood Disorders | 1 | 2015 | 125 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 655 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 559 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2019 | 482 | 0.030 |
Why?
|
| Age of Onset | 1 | 2016 | 598 | 0.030 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 149 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 393 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 914 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 2014 | 200 | 0.030 |
Why?
|
| Canada | 1 | 2014 | 323 | 0.020 |
Why?
|
| Needs Assessment | 1 | 2014 | 175 | 0.020 |
Why?
|
| Insulin-Secreting Cells | 1 | 2014 | 136 | 0.020 |
Why?
|
| Genome, Human | 1 | 2019 | 1324 | 0.020 |
Why?
|
| Liver | 1 | 2020 | 1800 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1623 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2016 | 2907 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 1798 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2015 | 1343 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2014 | 684 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2015 | 731 | 0.020 |
Why?
|
| Animals | 2 | 2022 | 33982 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4482 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 4716 | 0.010 |
Why?
|
| Mutation | 1 | 2018 | 6140 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 18268 | 0.010 |
Why?
|